研究单位：[1]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[2]Geneplus-Beijing Co. Ltd.[3]Chinese Cooperative Group of Liver Cancer (CCGLC) of CC-IHPBA[4]Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
This is an open-label, single-arm, phase 2 study. The purpose of study is to evaluate the feasibility and safety of hepatic artery infusion chemotherapy combined with lenvatinib and pucotenlimab as conversion therapy for unresectable intrahepatic cholangiocarcinoma.
